Integral Health Asset Management LLC Purchases 10,000 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Integral Health Asset Management LLC increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 8.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 130,000 shares of the medical research company’s stock after acquiring an additional 10,000 shares during the quarter. Quest Diagnostics comprises about 1.7% of Integral Health Asset Management LLC’s holdings, making the stock its 19th largest position. Integral Health Asset Management LLC’s holdings in Quest Diagnostics were worth $19,612,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Jefferies Financial Group Inc. grew its stake in shares of Quest Diagnostics by 17.0% during the fourth quarter. Jefferies Financial Group Inc. now owns 24,900 shares of the medical research company’s stock valued at $3,756,000 after purchasing an additional 3,627 shares during the last quarter. Ensign Peak Advisors Inc grew its stake in shares of Quest Diagnostics by 0.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 53,236 shares of the medical research company’s stock valued at $8,031,000 after purchasing an additional 485 shares during the last quarter. Ethic Inc. grew its stake in shares of Quest Diagnostics by 39.2% during the fourth quarter. Ethic Inc. now owns 10,052 shares of the medical research company’s stock valued at $1,516,000 after purchasing an additional 2,829 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of Quest Diagnostics during the fourth quarter valued at approximately $2,660,000. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of Quest Diagnostics by 2,570.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 79,369 shares of the medical research company’s stock valued at $11,974,000 after purchasing an additional 76,397 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO J. E. Davis sold 39,191 shares of Quest Diagnostics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $168.46, for a total transaction of $6,602,115.86. Following the completion of the transaction, the chief executive officer now owns 127,623 shares in the company, valued at approximately $21,499,370.58. This trade represents a 23.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael E. Prevoznik sold 528 shares of Quest Diagnostics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $172.61, for a total value of $91,138.08. Following the transaction, the senior vice president now owns 39,031 shares of the company’s stock, valued at $6,737,140.91. The trade was a 1.33% decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,250 shares of company stock worth $9,188,295 in the last quarter. Corporate insiders own 8.16% of the company’s stock.

Quest Diagnostics Price Performance

Shares of NYSE DGX opened at $176.96 on Monday. The stock has a market capitalization of $19.75 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 2.16 and a beta of 0.52. The business has a 50-day moving average of $169.70 and a 200-day moving average of $162.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.10 and a quick ratio of 1.02. Quest Diagnostics Incorporated has a fifty-two week low of $135.47 and a fifty-two week high of $179.32.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.06. The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.63 billion. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. As a group, sell-side analysts predict that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. UBS Group increased their price target on shares of Quest Diagnostics from $166.00 to $170.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. increased their price target on shares of Quest Diagnostics from $180.00 to $190.00 and gave the company a “neutral” rating in a research note on Tuesday, May 6th. Citigroup lowered shares of Quest Diagnostics from a “buy” rating to a “neutral” rating and set a $185.00 price objective on the stock. in a report on Tuesday, March 4th. Redburn Atlantic began coverage on shares of Quest Diagnostics in a report on Wednesday, April 2nd. They issued a “buy” rating and a $195.00 price objective on the stock. Finally, Robert W. Baird increased their price objective on shares of Quest Diagnostics from $191.00 to $194.00 and gave the company an “outperform” rating in a report on Wednesday, April 23rd. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Quest Diagnostics has an average rating of “Moderate Buy” and an average price target of $185.73.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.